NCT00437632 is a Phase 1 clinical trial of GSK598809 in Substance Dependence, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00437632?

NCT00437632 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00437632?

Interventions in NCT00437632: GSK598809, Placebo, Caffeine.

What condition does NCT00437632 study?

NCT00437632 studies Substance Dependence.

Is NCT00437632 still recruiting?

NCT00437632 is currently completed. Last updated 31 July 2017.

Last reviewed 2017-07-31 · How we verify

NCT00437632

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

Completed Phase 1 Last updated 31 July 2017

What this trial tests

Phase 1 trial testing GSK598809 in Substance Dependence in 104 participants. Completed in 22 August 2008.

Timeline

1 March 2007

Primary endpoint
22 August 2008

22 August 2008

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Primary purpose	treatment
Enrollment	104
Start date	1 March 2007
Primary completion	22 August 2008
Estimated completion	22 August 2008
Sites	1 location across United Kingdom

Drugs / interventions tested

GSK598809 — full drug profile →
Placebo
Caffeine (caffeine) — full drug profile →

Conditions studied

Substance Dependence — all drugs for Substance Dependence →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 50, any sex, with Substance Dependence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will evaluate the safety, tolerability and pharmacokinetics of repeat doses of GSK598809 in healthy volunteers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Keck TM, John WS, Czoty PW, Nader MA, et al · · 2015 · cited 79× · PMID 25826710 · DOI 10.1021/jm501512b
Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.
Keck TM, Burzynski C, Shi L, Newman AH. · · 2014 · cited 41× · PMID 24484980 · DOI 10.1016/b978-0-12-420118-7.00007-x

Verify or expand the search:

Other trials of GSK598809

Trials testing the same drug.

NCT00887367 — EtOH Interaction Study · Phase 1 · completed
NCT00728052 — A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers · Phase 1 · completed
NCT00605241 — A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward · Phase 1 · completed
NCT00437840 — A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809 · Phase 1 · completed

Other recruiting trials for Substance Dependence

Currently open trials in the same condition.

NCT06899308 — Health Surveillance at Constructor University Bremen (CUB) and Among HAW-Hamburg Employees · recruiting
NCT05679284 — A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs · recruiting
NCT04768920 — Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD) · NA · active not recruiting
NCT05410561 — Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients · NA · active not recruiting
NCT05348317 — Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders · NA · active not recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00437632 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 31 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00437632.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing